ImpediMed Ltd
ASX:IPD
ImpediMed Ltd
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
Record Revenue: Quarterly revenue reached a record $3.9 million, up 18% year-on-year and 8% on the prior quarter.
Cash Flow Improvement: Operating cash outflow dropped significantly to $2.9 million from $5.6 million last quarter, extending the company's cash runway.
Strong Reimbursement Gains: U.S. reimbursement coverage for SOZO in breast cancer-related lymphedema reached 93%, covering 323 million lives and up 5% from last quarter.
Mixed Sales Performance: Rest of world sales were strong, but U.S. sales for breast cancer-related lymphedema were softer than expected due to hospital budget constraints.
Growth Pipeline: Over 700 sales opportunities are in the pipeline, with confidence expressed in future growth as conditions stabilize.
Strategic Progress: FDA clearance was received for a new bilateral lymphedema algorithm, and a new 510(k) was filed for an expanded body composition offering.
Expansion in New Segments: Launch and positive feedback for SOZO Pro in heart health, wellness, and weight management markets, with first heart health sales in progress.
